Quick Answer
Centessa Pharmaceuticals plc reported Cash and Equivalents of $61.30 million for fiscal year 2025.
Centessa Pharmaceuticals plc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $61.30M | -84.0% |
| 2024 | $383.22M | +199.3% |
| 2023 | $128.03M | -67.5% |
| 2022 | $393.64M | -33.9% |
| 2021 | $595.08M | +8134.1% |
| 2020 | $7.23M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $50.81M | -87.1% | +14.8% |
| June 30, 2025 | $44.24M | -65.3% | -57.9% |
| March 31, 2025 | $105.16M | -11.0% | -72.6% |
| December 31, 2024 | $383.22M | +199.3% | -3.0% |
| September 30, 2024 | $395.03M | +130.3% | +210.1% |
| June 30, 2024 | $127.37M | -12.3% | +7.7% |
| March 31, 2024 | $118.22M | -54.5% | -7.7% |
| December 31, 2023 | $128.03M | -67.5% | -25.3% |
- Centessa Pharmaceuticals plc showed a decrease of -84.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Centessa Pharmaceuticals plc’s cash and equivalents has grown by 748.2% (from $7.23 million to $61.30 million).
- The most recent figure is from Centessa Pharmaceuticals plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: